Roxithromycin and lower respiratory tract infections.
Scott
W G
WG
Cooper
B C
BC
Scott
H M
HM
Karalus
N C
NC
Garrett
J
J
Lang
S D
SD
D000328:Adult; D000658:Amoxicillin / Q000191:economics / Q000627:therapeutic use; D019980:Amoxicillin-Potassium Clavulanate Combination; D002969:Clavulanic Acids / Q000191:economics / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000188:drug therapy*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004359:Drug Therapy, Combination / Q000627:therapeutic use*; D006801:Humans; D009520:New Zealand; D012141:Respiratory Tract Infections / Q000188:drug therapy*; D015575:Roxithromycin / Q000191:economics / Q000627:therapeutic use*
D002969:Clavulanic Acids; D015575:Roxithromycin; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin